Group 1 - The core point of the article is that Zhongyuan Qihua (中源协和) holds an 11.05% stake in Beike Biotechnology (北科生物), which is involved in a diabetes treatment project approved for trial in Hainan Boao [2] - Beike Biotechnology is a subsidiary in which Zhongyuan Qihua is a shareholder and has independent operational capabilities [2] - Investors are encouraged to follow Beike Biotechnology's official platforms for updates regarding its IPO application [2]